1 Optimal age targeting for pneumococcal vaccination in older adults; a

2 modelling study.

3

4 Authors:

- 5 Deus Thindwa, MSc^{1,2,3}, Samuel Clifford, PhD^{1,2}, Jackie Kleynhans, MSc^{4,5}, Prof Anne von
- 6 Gottberg, PhD^{4,6}, Sibongile Walaza, PhD⁴, Susan Meiring, MBChB⁴, Todd D Swarthout, PhD
- 7 ^{3,7}, Prof Elizabeth Miller, FMedSci², Prof Peter McIntyre, D Med Sc⁹, Prof Nick Andrews, PhD
- ⁸, Zahin Amin-Chowdhury, PhD ⁸, Norman Fry, PhD ⁸, Kondwani Jambo, PhD ^{3,10}, Prof Neil
- 9 French, PhD^{3,11}, Samanta Cristine Grassi Almeida, PhD¹², Prof Shamez Ladhani, PhD⁸, Prof
- 10 Robert S Heyderman, PhD^{3,7}, Prof Cheryl Cohen, PhD^{4,5}, Prof Maria Cristina de Cunto
- 11 Brandileone, PhD¹², Prof Stefan Flasche, PhD^{1,2}.
- 12

13 Institutions:

- ¹Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene &
- 15 Tropical Medicine, London, UK
- 16 ² Department of Infectious Disease Epidemiology London School of Hygiene & Tropical
- 17 Medicine, London, UK
- 18 ³ Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi
- ⁴ Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases
- 20 of the National Health Laboratory Service, Johannesburg, South Africa
- ⁵ School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
- ⁶ School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
- ⁷ Division of Infection and Immunity, University College London, London, UK

- ⁸ Immunisation and Countermeasures Division, UK Health Security Agency, London, UK
- ⁹ University of Otago, Dunedin, New Zealand
- ¹⁰Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
- 27 ¹¹ Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
- 28 ¹² National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis,
- 29 Pneumonia and Pneumococcal Infection, Centre of Bacteriology, Brazil
- 30

31 **Corresponding author:**

- 32 *Email:<u>deus.thindwa@lshtm.ac.uk</u>
- 33 <u>Phone: +265997788370</u>
- 34 Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi & Department of
- 35 Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel
- 36 Street, London, UK
- 37

38 Abstract

39 Background

- 40 Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the
- 41 population size benefiting from pneumococcal vaccines and the robustness of the immunogenic
- 42 response to vaccination decline. This poses a conundrum for identifying the optimal age for
- 43 vaccination. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning
- 44 VE impact on optimal age for single-dose pneumococcal vaccination.
- 45

46 Methods

47 Age- and vaccine-serotype-stratified IPD incidence from routine surveillance of adults \geq 55 years

48 old (y) in Brazil, England, Blantyre (Malawi), and South Africa, ≥4-years after infant-

- 49 pneumococcal vaccine introduction and before 2020, was used to parameterise exponential
- 50 growth models of increasing IPD risk with age. A piecewise-constant model estimated VE and
- 51 waning VE from prior studies. All estimates were then combined in a cohort model to assess the
- 52 vaccine preventable IPD burden of delivering 13-, 15-, 20-valent conjugate or 23-valent

53 polysaccharide vaccines at various ages.

54

55 Findings

56 In Brazil, Malawi, South Africa and England 51%, 51%, 54% and 39% of adults older than 55y

57 were younger than 65y old. A smaller share of IPD was reported among adults <65y old in

- 58 England (4,657 annual cases; 20% <65y) compared to Brazil (186; 45%), Malawi (4; 63%), or
- 59 South Africa (134, 48%). PCV13- and PPV23-serotypes were estimated to cause 39% and 85%
- 60 of IPD cases on average across settings. Vaccination at 55y in Brazil, Malawi, and South Africa,

61	and at 70y in England had the greatest potential for IPD prevention with 38%, 31%, 27%, 8% of
62	IPD preventable if using PCV13, 44%, 32%, 30%, 13% with PCV15, 65%, 69%, 53%, 37% with
63	PCV20, and 30%, 29%, 20%, 14% with PPV23, respectively. Vaccination efficiency or cost
64	effective use was optimal in 60-65y in Brazil, Malawi and South Africa, and in 80-85y in
65	England.
66	
67	Interpretation
68	In low/middle-income countries, pneumococcal vaccines may prevent a substantial proportion of
69	the residual IPD burden if administered earlier in adulthood than is typical in high-income
70	countries.
71	
72	Funding
73	UK National Institute for Health and Care Research.

75 **Research in context**

76 Evidence before this study

77 A recent review conducted for the World Health Organisation (WHO) Scientific Advisory Group 78 of Experts (SAGE) working group on pneumococcal vaccines reviewed the evidence on the 79 efficacy, effectiveness and potential impact of pneumococcal vaccines in older adults. At the 80 time, little evidence was identified to support recommendations for the age of pneumococcal 81 vaccination in older adults, particularly in LMICs. We did an updated search of PubMed, 82 Medline, Embase and Web of Science for studies on age targeting for pneumococcal vaccination 83 in older adults published from Jan 1, 2003 to June 30, 2022, using the search terms "(optimal age 84 targeting OR age targeting OR timeliness) AND (pneumococcal vaccination OR pneumococcal 85 vaccines) AND (adults OR older adults OR elderly)". We identified one study on the role of 86 timeliness in the cost-effectiveness of older adult vaccination in Australia. This study explored 87 the impact of the timeliness of pneumococcal conjugate vaccination (PCV) in older adults and 88 found that more hospitalisations and deaths can be prevented if PCV13 was given to 70y old than 89 as recommended at 65y. On the other hand, most low-income countries (LICs) and middle-90 income countries (MICs) do not have routine older adult pneumococcal vaccination programmes, 91 despite often less indirect protection from childhood PCV programmes and high burden of 92 vaccine preventable disease. The implications of differences in population demographics and risk 93 for IPD compared to high income countries on the optimal age for pneumococcal vaccination in 94 LICs/MICs are unknown.

95

96 Added value of this study

97	This multicountry study uses data from long-standing older adult pneumococcal surveillance
98	programmes at the national/sub-national level, to explore the optimal age-targeting for a single-
99	dose pneumococcal vaccination against vaccine-serotype-IPD in older adults living without
100	human immunodeficiency virus in LIC (Malawi), MICs (Brazil, South Africa), and HIC
101	(England). We show that despite mature pneumococcal infant vaccination programmes there is a
102	substantial burden of vaccine preventable pneumococcal disease remaining in the four countries
103	considered. Vaccinating at 55y in the LICs/MICs was optimal whereas vaccinating at 70y
104	prevented most IPD cases in England than vaccinating at other ages. While the number of older
105	adults needed to vaccinate to prevent an IPD case may be higher for programmes vaccinating
106	older individuals, vaccination efficiency or vaccine cost effective use was optimal in 60-65y in
107	LICs/MICs, and in 80-85y in England.
108	
109	Implications of all available evidence
110	LICs/MICs with a mature infant immunisation programme for pneumococci and a remaining
111	high burden of vaccine preventable pneumococcal disease in older adults may consider
112	implementation of a vaccination programme for older adults, albeit at a younger age than typical
113	in HICs. Affordability and cost-effectiveness of an adult vaccination programme as well as the

- 114 indirect effects following potential changes to higher valency infant PCV vaccination
- 115 programmes will also need to be considered.

117 Introduction

118	Streptococcus pneumoniae (pneumococcus) is a major global cause of childhood mortality [1,2],
119	but also causes a high burden of disease among older adults [2,3]. Two vaccines have been used
120	to prevent pneumococcal disease in older adults \geq 55 years-old (y): a 13-valent pneumococcal
121	conjugate vaccine (PCV13) and a 23-valent pneumococcal polysaccharide vaccine (PPV23) [4].
122	Recently, 15- and 20-valent PCVs (PCV15, PCV20) have also been licensed and recommended
123	for older adults in the United States [5,6].
124	
125	Although routine infant PCV programmes have generated indirect protection against vaccine-
126	serotype (VT) pneumococcal disease among older adults [7,8], a substantial disease burden
127	remains, composed of serotypes not targeted by childhood PCV programmes and residual
128	circulation of VT [2,9]. Among high-income countries (HICs) with a mature infant-PCV13
129	programme, PCV13- and PPV23-targeted serotypes caused about 15% and 42%, respectively, of
130	invasive pneumococcal disease (IPD) in older adults [2,10]. Routine infant-PCV programmes in
131	many low- and middle-income countries (LICs and MICs) have often led to less pronounced
132	herd effects with continued circulation of VTs especially in the unvaccinated adult population
133	[11,12], who happen to have no access to routine pneumococcal vaccination [13].
134	
135	The recommended age for pneumococcal vaccination in older adults in HICs is typically either at
136	60y or 65y [4,14]. However, yet only a single study has assessed the age at which the most gain
137	from such programme is seen (in the Australian context) [15]. As the risk of severe

138 pneumococcal disease increases with age [10,15], waning of protection from vaccination early in

139 older adulthood risks disease at ages of highest disease incidence, whereas vaccination late in

older adulthood cannot address the substantial disease burden among a large pool of susceptibleolder adults who have not yet been vaccinated.

142

143 In this modelling study, we explore the optimal age-targeting for a single-dose pneumococcal

144 vaccination against VT-IPD in older adults living without human immunodeficiency virus (HIV)

145 in Brazil, England, Malawi, and South Africa.

146

147 Methods

148 Study sites

We included England (HIC), Brazil and South Africa (MICs), and Blantyre in Malawi (LIC) in
this analysis, to explore the optimal age-targeting for pneumococcal vaccination, as all have

151 long-standing adult pneumococcal surveillance programmes at the national or sub-national level

152 [9,16–18]. More details on the respective IPD surveillance systems are in the appendix (Text

153 S1). Infant-PCV13 has been in use since 2011 in South Africa (two primary doses and booster

154 (2+1) schedule) and Malawi (3+0 schedule), with estimated 90-95% vaccination coverage

155 [11,18]. In England, routine PCV13 immunisation programme with 92% booster dose coverage

has been in place since 2010, initially using a 2+1 schedule, switching to 1+1 schedule in 2020

157 [19]. In Brazil, a routine infant-PCV10 programme was implemented in 2010 with a 3+1

schedule, switched to a 2+1 in 2016, with average coverage of 94% between 2015 and 2017 [20].

159

160 In England, PPV23 has been recommended for risk groups since 1992, and for all adults aged

 $\geq 65y$ since 2003, with single-dose coverage rising to 70% in 2018 [17,21]. In Brazil, PPV23 is

162 not included in the national immunisation programme but has been recommended for use since

the 1980s, and is available free of charge at the centers of special immunobiological for people
above 2 years old including institutionalised older adult, and thus coverage of <1% among all
older adults above 60y [22]. In South Africa, although adult pneumococcal vaccination is
recommended, there is no routine programme nor nationally accepted guidelines [23]. In
Malawi, neither routine adult pneumococcal vaccination programme nor national guidelines exist
[13].

169

170 **Population demographics**

171 The population demographics for adults \geq 55y were obtained in annual age strata from population 172 censuses conducted in 2010 for Brazil [24], 2011 England (updated in 2017) [25], 2018 Malawi 173 [26], and 2011 South Africa [27]. To align with IPD surveillance timelines in respective 174 countries, annual age population censuses were projected at a constant growth rate of 0.8%175 during 2010-2016 in Brazil and 1.3% during 2011-2016 in South Africa [28,29]. For England 176 and Malawi, 2017 and 2018 populations already aligned with IPD surveillance time. Annual age 177 population estimates were smoothed to reduce demographic stochasticity in downstream results 178 by applying a 5-year moving average [30].

179

180 Invasive pneumococcal disease burden

181 For each site we used data on IPD burden in older adults in the presence of a mature infant-PCV

182 programme, defined as at least 4 years after infant-PCV introduction, to avoid inclusion of

183 ongoing changes in IPD burden attributable to indirect effects from the childhood programme

184 [31]. The number of IPD cases caused by all serotypes, and serotypes targeted by PCV13,

185 PCV15, PCV20 and PPV23 in annual age strata (55y to 85y+) were obtained from laboratory-

based surveillance in each country (Fig S1). We calculated age and serotype distribution and 186 187 proportionally inflated estimates by the number of IPD cases without serotyping available to 188 correct for proportion serotyped. In England, where PPV23 has been in use in 65y+ at 70% 189 uptake, we back-inflated the number of IPD cases in order to correct for the fact that in the 190 absence of PPV23 vaccination, IPD incidence would be higher, especially in ages eligible for 191 PPV23 vaccination. Details about back-inflation calculation are in the appendix (Text S2). Age 192 aggregated (55-59y, 60-64y, 65-69y, 70-74y, 75-79y, 80-84y and 85y+) and serotype-specific 193 IPD incidence was calculated by dividing by the age-group specific population estimates. Due to 194 the small number of reported IPD cases and incomplete serotyping information in Malawi, we 195 only calculated the serotype distribution for all cases and assumed that it was the same in each 196 age group.

197

198 The focus of this study was vaccination strategies for older adults living without HIV because 199 adults living with HIV often have independent pneumococcal vaccine recommendations [12]. 200 Thus, for adult HIV prevalence of >10% in South Africa [32], we adjusted IPD incidence 201 estimates for HIV status. For 201 (18.7%) reported IPD cases, HIV status was reported. We took 202 a 30% random subset of IPD cases with known HIV status and estimated a 49.3% proportion of 203 IPD cases without HIV for this subset. We assumed that a similar proportion of IPD cases with 204 unknown HIV status would be without HIV. We further accounted for similar serotype 205 distribution in those with and without HIV. In Malawi, IPD cases could not be stratified by HIV 206 infection status, and thus we used the age-dependent HIV infection rates in the general adult 207 population and applied the relative propensity for IPD in older adults with and without HIV from 208 South Africa to infer the incidence of IPD among older adults without HIV by age.

210	We modelled the reported age-specific IPD incidence among older adults without HIV per
211	country as a function of age using an exponential growth model. Details about model fitting are
212	in appendix (Text S3). The expected incidence at age <i>a</i> is:
213	
	$E(I a) = \gamma e^{\beta a} \dots $
214	where $E(I a)$ is the expected IPD incidence at age <i>a</i> , β is the growth rate, and γ is a constant of
215	proportionality. Uncertainty was obtained by bootstrap sampling 1000 times using the fitted
216	parameter means and covariance matrix and summarisation of uncertainty via 95% quantiles of
217	samples.
218	
219	PCV and PPV vaccine efficacy/effectiveness
220	A previous systematic review identified studies that estimate vaccine efficacy/effectiveness (VE)
221	against IPD from time since vaccination [2]. Four observational studies in HICs estimated VE at
222	two or more time points for PPV23 [17,21,33–35]. One randomised controlled trial estimated VE
223	against IPD and community-acquired pneumonia (CAP) following PCV13 use in older adults
224	and found consistent 75% and 46% respective efficacy for 5 years following vaccination [36,37].
225	Thus, we assumed that PCVs' efficacy against IPD would continue to stay stable for five years,
226	and thereafter decline in the same way as the scenario for PPV23. We represented the VE as a
227	function of time since vaccination using piecewise constant models. The piecewise constant
228	functions are shown in appendix (Fig S2, Fig S3). The VE was sampled using bootstrap
229	sampling from a normal distribution centred on the mean VE at that time and standard deviation
230	derived from the reported 95% interval.

231

232	Little evidence is available on changes in PPV23 or PCV13 VE by age at administration [15,38].
233	A UK study found no significant difference in VE of PPV23 when administered to 65y, 75y or
234	85y adults, although point estimates suggested a decline with age [17]. There is also some
235	evidence that immune response to immunisation is partially impaired later in life [2]. Thus, as a
236	base case we assumed that VE for all formulations was independent of the age of administration,
237	but included a sensitivity analysis assuming that VE was 33% less of initial VE if given to adults
238	aged 65-74y and 44% less of initial VE if given to adults aged 75+y using point estimates of VE
239	of PPV23 against IPD in the 5 years following administration in adults <65y of 54%, decreasing
240	to 36% for 65-74y and 30% for 75y+ [17].

241

242 PCV and PPV vaccine impact model

243 We developed a cohort model to simulate the risk for IPD in adults >55y in all four countries. 244 Time steps in the model were set at 1 year. Age-dependent all-cause mortality was set to match 245 observed population demographics of older adults living without HIV in all countries, and age-246 dependent IPD risks were set to match fitted IPD incidence in respective countries and years. We 247 calculated the vaccine preventable number of IPD cases as the lifetime number of cases averted 248 through vaccinating 100% of adults at the specified age for vaccination under the scenarios of 249 age-dependency on initial VE and waning VE. We estimated the efficiency of the alternative 250 strategies by reporting the number of age cohort individuals needed to vaccinate (or number of 251 doses needed to administer to age cohort) in order to prevent a case.

- 253 Sensitivity analysis assessed the influence of age-dependent initial VE on vaccine impact. All
- analyses were conducted using R language v4·1·1, with data and code available through GitHub
- 255 <u>https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines.</u>
- 256

257 Ethical approval

- 258 In Brazil, no patient consent is required since data are obtained through the National
- 259 Epidemiological Surveillance approved by the Scientific Committee of the Instituto Adolfo Luiz
- 260 (CTC 61-M/2020). In England, the UK Health Security Agency (UKHSA) has legal permission,
- 261 provided by Regulation 3 of The Health Service Regulations 2002, to monitor the safety and
- 262 effectiveness of vaccines for national surveillance of communicable diseases
- 263 (http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made). In Malawi, the study
- 264 protocol was approved by Malawi's National Health Sciences Research Committee (protocol
- 265 867), Kamuzu University of Health Sciences College of Medicine Research Ethics Committee
- 266 (COMREC) (P·01/08/609 and P·09/09/826), and the University of Liverpool Research Ethics
- 267 Committee (RETH490). Individual patient informed consent was not required for the use of
- 268 publicly available anonymised routine samples as per COMREC guidelines 5.6. In South Africa,
- 269 ethical approval to conduct laboratory-based and enhanced surveillance was obtained from the
- 270 Health Research Ethics Committee (Human), University of Witwatersrand (M140159) and
- 271 individual patient consent was obtained for clinical data collection at enhanced surveillance sites.
- 272 Ethical approval for this study was granted by the London School of Hygiene and Tropical
- 273 Medicine (25787).
- 274

275 **Results**

276 **Population demographics and IPD burden**

- 277 Of the 27.7 million (m) older adults (≥55y) in Brazil, 16.5m in England, 66,589 in Blantyre
- 278 Malawi, and 6.9m in South Africa, the proportion of older adults aged 55y to <65y was 51.3%,
- 279 51.0% and 53.8% in Brazil, Malawi and South Africa, substantially higher than the 39.1% in
- England. During the study period, Brazil (2015-2017), England (2016-2019), Malawi (2016-
- 281 2019) and South Africa (2015-2018) reported 559, 13,971, 19, 537 IPD cases in adults ≥55y
- equivalent to an average annual number of cases of 186.3, 4,658.0, 4.8 and 134.3, respectively.
- 283 Of these in the \geq 55y, 44.5%, 19.9%, 62.5%, and 47.9% were in <65y olds. Cases caused by
- 284 PCV13 serotypes accounted for 61.4% (343/559), 21.0% (2,936/13,971), 41.0% (8/19), and
- 285 32.8% (176/537) of all IPD in Brazil, England, Malawi and South Africa, and PPV23 serotypes

286 for 97.9% (547/559), 72.5% (10,126/13,971), 94.8% (18/19), and 73.2% (393/537), respectively

287 (Fig 1).

- 288
- 289 The exponential model fitted the increase in IPD incidence with age well. The estimated IPD

incidence in 85y was higher than in 55y olds by 2.48-fold (95% confidence interval [95% CI]:

291 2·13-2·83) in Brazil, 2·19-fold (95% CI: 0·14-4·51) in Malawi, and 2·25-fold (95% CI: 1·88-

292 2.62) in South Africa. In England the incidence increased more steeply to 11.00-fold (95% CI:

293 10.90-11.40) higher in 85y than 55y (Fig 1).

294


295 While the estimated number of IPD cases declined with age in Brazil, Malawi and South Africa,

it increased in England. On the other hand, age-specific IPD incidence of total IPD incidence

297 (age-scaled IPD incidence) increased with age in all settings irrespective of serotype, and with

high uncertainty in Malawi due to small case numbers (Fig S4, Fig S5).





300 Figure 1. Population demographics and invasive pneumococcal disease (IPD) burden. (Left 301 panel) Among individuals who are aged \geq 55y, the proportion/share in annual age groups in 302 Brazil, England, Malawi and South Africa as estimated from their national censuses, based on 303 five years rolling average smoothed population counts to control for demographic stochasticity; 304 (Middle panel) Number of IPD cases in five year age bands in older adults stratified by serotype 305 in Brazil (2015-2017), England (2016-2019), Blantyre Malawi (2016-2019) and South Africa 306 (2015-2018), reported from at least four years post-infant PCV introduction in each country. 307 (Right panel) Serotype-specific reported and predicted IPD incidence per 100,000 population 308 between 55y and 90y in Brazil, England, Malawi and South Africa. The black circle represents 309 estimated IPD cases per 100,000 population, the vertical line through the circle represents a 95% 310 uncertainty interval in estimated IPD case number, the curve line is the exponential model fit and 311 the ribbon represents a bootstrapped 95% confidence interval for the fitted line. The red and

black points for England represent estimated IPD cases in the presence and absence of PPV23
vaccination, respectively.

314

315 **Optimal age for vaccination**

316 The optimal age for vaccination, the age of a single-dose vaccination that could prevent most

317 IPD cases, is attained when vaccines are given earlier in the considered age range in the

318 LIC/MIC setting, but not for England (Fig 2). In the base scenario with rapid waning of PPV23

319 VE, we found that the highest proportion of all IPD cases could be preventable if adults aged 55y

320 are vaccinated in Brazil (30.5%, 22.4-43.3), in Malawi (31.0%, 7.7-96.6), and in South Africa

321 (20.0%, 13.7-28.7), and if adults aged 70y are vaccinated in England (13.7%, 10.8-17.4)

322 compared to a scenario without vaccination (Table S1). Also, In the base scenario with rapid

323 waning VE, higher proportion of all preventable cases are estimated for using PCV20 vs PPV23

relative to a scenario without vaccination in Brazil (61.3%, 42.7-89.2) vs (30.1%, 20.6-43.5),

325 Malawi (64.5 %, 13.0-92.2) vs (28.5%, 5.7-73.3), and South Africa (53.1%, 39.7-73.2) vs

326 (19.8%, 13.0-29.2) among adults aged 55y, and in England (27.2%, 21.6-34.5) vs (13.6%, 10.4-


327 17.6) among adults aged 70y, respectively (Table S2). Furthermore, higher proportion of IPD

328 cases are preventable under slow vs rapid waning of PPV23 VE among adults aged 55y in Brazil

329 (40.7%, 29.0-57.1) vs (30.1%, 20.6-43.5), Malawi (38.6%, 8.0-77.2) vs (28.5%, 5.7-73.3), South

330 Africa (26.4%, 18.2-38.3) vs (19.8%, 13.0-29.2), and among adults aged 70y in England (17.5%,


331 13·8-22·0) vs (13·6%, 10·4-17·6), respectively (Table S3).



333 Figure 2. The impact of routine pneumococcal vaccination in older adults aged \geq 55 years old (y). 334 The expected absolute number of total IPD cases averted for the rest of age cohort lifetime by 335 vaccinating every older adult in the age cohort stratified by country and vaccine product, under 336 the scenario of age-independent initial vaccine efficacy/effectiveness (VE) and waning VE in 337 Brazil, England, Malawi and South Africa. The lines represent cohort model mean estimates and 338 the shaded ribbon represents 95% bootstrap confidence intervals for the mean estimates. The X 339 corresponds to the optimal age for pneumococcal vaccination. In Brazil, Malawi and South 340 Africa, most cases are preventable at age 55y whereas in England this is achieved at age 70y. 341

342 The optimal age for vaccinating the lowest number of individuals with single dose pneumococcal 343 vaccine to prevent a reported case of IPD (vaccination efficiency) is estimated to differ by 344 country, vaccine product or waning VE assumption (Fig 3). In a base case scenario with rapid 345 waning of PPV23 VE, optimal age for vaccination efficiency is achieved through vaccination at

- 346 60y in Malawi 684 (244-2,009), 65y in Brazil 10,283 (8,165-13,162), and 75y in South Africa
- 347 3,643 (3,004-4,555) and at 80y in England 352 (287-438) (Table S4).
- 348



349 Figure 3. The efficiency of routine pneumococcal vaccination in older adults aged ≥55 years old 350 (y). The number of individuals needed to vaccinate to prevent a case in each age of vaccination, 351 stratified by country and vaccine product, under assumptions of age-independent initial vaccine 352 efficacy/effectiveness (VE) and waning VE in Brazil, England, Malawi and South Africa. The 353 lines represent cohort model mean estimates and the shaded ribbon represents 95% bootstrap 354 confidence intervals for the mean estimates. The X represents the optimal age for efficiency of 355 pneumococcal vaccination. Efficiency of vaccination varies by waning VE assumption and 356 country reflecting sensitivity in reported invasive pneumococcal disease cases.

357

358 Sensitivity analyses

359 If a scenario of age-dependent initial VE is considered in a sensitivity analysis, vaccine impact 360 (total cases averted) remains maximum at 55y in Brazil, Malawi, and South Africa irrespective 361 of vaccine product and assumption of waning VE as was the case with the base case scenario of 362 age-independent initial VE. In contrast, optimal age for vaccination drops to 60y in England (Fig. 363 S6). In this scenario, the optimal age of vaccination efficiency is achieved by vaccination of 60y 364 in Brazil, Malawi and South Africa, irrespective of vaccine product or assumptions of waning 365 VE. In England, efficiency is achieved in 60y age cohort for PCV20 and PPV23 irrespective of waning VE assumption, and in 80y or 85y for PCV13's and PCV15's slow or fast waning VE, 366 367 respectively (Fig S7).

369 **Discussion**

370 We have assessed the optimal age-targeting for a single-dose PCV/PPV vaccination against VT-371 IPD in older adults ≥55y in Brazil, England, Malawi, and South Africa and find that vaccinating 372 at 55v in considered LIC/MICs maximises preventable burden of IPD while vaccination at 70v is 373 optimal in England. These findings suggest that the optimal age for vaccination may differ 374 between countries and is driven by population age demographic, age-dependent IPD incidence 375 and VE. Our findings were robust across pneumococcal vaccine products, and to alternative 376 assumption on waning of VE. 377 378 The increasing incidence of IPD in older adulthood is outweighed by many more individuals in 379 the fifties in LIC/MICs. The different age population structure in England, with a higher 380 proportion of \geq 55y in the middle to older adult ages, results in the optimal age for vaccination 381 peaking later at 70y. The optimal age of vaccination in England also aligns with results from an 382 Australian study that explored the role of timeliness in the cost-effectiveness of older adult 383 vaccination and found that most deaths and hospitalisations were prevented if PCV13 was given 384 to 70y, a peak age of prevented burden before dropping in remaining older ages [15].

385

The age with lowest number of individuals needed to vaccinate to prevent a case (optimal age of vaccination efficiency) differed by country, vaccine product or assumption of waning VE, in part reflecting the differences in sensitivity of IPD surveillance and the complex interplay between different factors influencing vaccination efficiency. Although this finding accounts for life expectancy, it does not consider quality-adjusted life-years losses due to IPD which could shift

the optimal age of vaccination efficiency downwards because more individuals affected by IPDwould be added to the fifties than elderly.

393

394 Our cohort model prediction of more preventable cases in all settings with the use of PCV20 vs 395 PPV23 under similar conditions reflects higher efficacy/effectiveness of PCV20 than PPV23 [2]. 396 Moreover, a larger number of IPD preventable cases by PCV20 than lesser-valent PCVs 397 underlines the importance of additional serotypes 8, 10A, 11A, 12F and 15B and/or 22F, 33F 398 covered by PCV20 in the remaining IPD burden in the mature infant-PCV era [10]. Generally, 399 other disease endpoints including non-bacteraemic pneumonia may also be important for vaccine 400 choice e.g., PCV13 is shown to be more efficacious in preventing VT non-bacteraemic 401 pneumonia than PPV23 (46% vs 21%) [2], and if included in this analysis, it may likely heighten 402 PCV13 impact to similar levels or higher than PPV23 in England, albeit with higher vaccine 403 cost. With the likely upcoming use of PCV15 and PCV20 in infants in the near future [39], the 404 vaccine preventable fraction of adult disease is likely to diminish correspondingly because of the 405 indirect effects of such infant programme, and thus reducing the benefit of adult programmes 406 that target the same serotypes as those targeted in infants. On the other hand, PCV21 targets most serotypes not targeted by PPV23 or PCV20 [40], which could likely improve tackling the 407 408 remaining burden of pneumococcal disease in older adults, in the long absence of vaccines that 409 target surface proteins common to all serotypes [41]. However, for LICs/MICs, PCV15, PCV20 410 and PCV21 may likely not be accessible soon due to their high initial costs. 411

412 Of note, we excluded older adults with HIV because they typically are considered separately for413 pneumococcal vaccination because of their high risk of disease before they reach old age.

414 However, inclusion of older adults with HIV may likely elevate IPD burden in early older 415 adulthood because of their huge presence in early than late adulthood due to survival bias 416 thereby re-enforcing vaccinating early in older adulthood, particularly in Malawi and South 417 Africa where adult HIV prevalence is relatively high [29]. In this analysis, the contribution of 418 PCVs' indirect protection from older adults to overall vaccine impact is ignored because older 419 adults have low carriage rates unlike children who are the main transmitters, and the use of 420 PPV23 does not protect against carriage and therefore unlikely to generate substantial herd 421 immunity [42]. Sequential dosing of vaccine regimens was not modelled, although PCV15 422 followed by PPV23 is now recommended by the advisory committee on immunisation practices 423 (ACIP) in the United States [43]. This sequential regimen would likely generate higher impact 424 than a single dose of PCV20 or PPV23, albeit with cost-effectiveness implications that need 425 further research, particularly in LICs [2].

426

427 PCVs and PPV23 are reported to have limited efficacy/effectiveness against serotype 3 428 pneumococcal carriage and disease [44], and our inclusion of serotype 3 IPD cases in this 429 analysis imply that our vaccine impact estimates are likely biased upwards. PPV23 is already in 430 use in $\geq 65y$ in England [17], and we show in this analysis that the effects of PPV23 use have 431 reduced the original IPD burden (Fig 1), and without adjusting for the current PPV23 vaccination 432 programme, our optimal age for vaccination in this country may be overestimated. Reported IPD 433 case data in LMICs are usually incomplete or under-ascertained due to limited resources e.g. 434 only 19 IPD cases were reported in Malawi and even less so when stratified by age and serotype 435 [3]. Thus, our results should be cautiously interpreted. Despite potential biases of case 436 underreporting, it seems reasonable to assume that underreporting is consistent across adult age

groups, such that a relative change in IPD incidence by age to identify optimal age-targetingvaccination is less likely affected.

439

- 440 In conclusion, the optimal age-targeting for vaccination is largely driven by population age
- 441 demographic, age-dependent IPD incidence and VE. In contrast to the typical use in adults in
- 442 HICs, we find that pneumococcal vaccination in 55y older adults in LIC/MICs may be the most
- 443 effective strategy in reducing the IPD burden among older adults without HIV, although
- 444 affordability, cost-effectiveness and infant vaccination plans will also need to considered when
- 445 designing a strategy to protect older adults against pneumococcal disease.

447 Acknowledgements

- 448 We thank all the individuals working in respective invasive pneumococcal disease (IPD)
- 449 surveillance and laboratory management teams in the four countries for providing important data
- 450 on IPD isolates and related causing serotypes. DT, KCJ, SF NF, RSH, and TDS are supported by
- 451 the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal
- 452 Pathogens (MPRU) where RSH is a NIHR Senior Investigator. In addition, SF is supported by a
- 453 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society. We
- 454 would like to thank Stephen Gordon of Liverpool School of Tropical Medicine for insightful
- 455 discussion and feedback at the initial stage of this work.
- 456

457 Author contributions

- 458 Conceptualization; DT, SC, SF, EM, PM, NA.
- 459 Data curation; DT, JK, SM, TDS, ZAC, NFY, SCGA, MCdCB.
- 460 Formal analysis; DT, SC, SF.
- 461 Funding acquisition; DT, NF, SL, RSH, CC, MCdCB, SF.
- 462 Investigation; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL,
- 463 RSH, CC, MCdCB, SF.
- 464 Methodology; DT, SC, NF, SL, RSH, CC, MCdCB, SF
- 465 Project administration; JK, AvG, SW, SM, TDS, ZAC, NFY, KJ, NF, SCGA, SL, RSH, CC,
- 466 MCdCB.
- 467 Resources; DT, NF, SL, RSH, CC, MCdCB, SF.
- 468 Software; DT, SC.
- 469 Supervision; SF, NF

- 470 Validation; SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL, RSH,
- 471 CC, MCdCB, SF.
- 472 Visualization; DT, SC.
- 473 Writing original draft; DT, SC, SF.
- 474 Writing review & editing; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ,
- 475 NF, SCGA, SL, RSH, CC, MCdCB, SF.
- 476 All authors read and approved the final manuscript.
- 477

478 Data availability

- 479 An R script that was used to analyse the datasets and aggregated data are available in the GitHub
- 480 repository <u>https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines.</u>
- 481

482 **Declaration of interests**

- 483 The authors declare no competing interests.
- 484

485 **Role of the funding source**

486 A project grant from the National Institute for Health and Care Research (NIHR) Global Health

487 Research Unit on Mucosal Pathogens (MPRU) is supported using UK aid from the UK

- 488 Government (Grant 16/136/46). The views expressed in this publication are those of the
- 489 author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
- 490 The MLW Clinical Research Programme is supported by a Strategic Award from the Wellcome,
- 491 UK. This research was funded in whole, or in part, by the Wellcome Trust [Grant number
- 492 208812/Z/17/Z]. For the purpose of open access, the author has applied a CC BY public

- 493 copyright licence to any Author Accepted Manuscript version arising from this submission. The
- 494 funders had no role in study design, collection, analysis, data interpretation, writing of the report
- 495 or in the decision to submit the paper for publication. The corresponding author and senior
- 496 authors had full access to the study data, and together, had final responsibility for the decision to
- 497 submit for publication

499 **References**

- Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of
 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era
 of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob
 Health. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- Department of Immunization, Vaccines and Biologicals. WHO | SAGE Yellow Book for
 October 2020 [Internet]. Geneva, Switzerland: WHO; 2020 Oct p. 20. Available:
 http://www.who.int/immunization/sage/meetings/2020/october/presentations_background_
 docs/en/
- Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, et al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms. Multidisciplinary Digital Publishing Institute; 2021;9: 742. doi:10.3390/microorganisms9040742
- 4. Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al.
 Adult vaccination for pneumococcal disease: a comparison of the national guidelines in
 Europe. Eur J Clin Microbiol Infect Dis. 2019;38: 785–791. doi:10.1007/s10096-01903485-3
- 5. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability,
 and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults
 60 to 64 Years of Age. Clin Infect Dis. doi:10.1093/cid/ciaa1045
- 520 6. CDC Advisory Committee on Immunization Practices (ACIP). EtR for PCV15 use among
 521 adults ≥65 years old | CDC [Internet]. 27 Jan 2022 [cited 8 Feb 2022]. Available:
 522 https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-based-etr.html
- Flasche S, Hoek AJV, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JAG, et al. The
 Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While
 Sustaining Herd Immunity in High-Income Countries. PLOS Med. 2015;12: e1001839.
 doi:10.1371/journal.pmed.1001839
- von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al.
 Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. N Engl J Med.
 2014;371: 1889–1899. doi:10.1056/NEJMoa1401914
- Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, et al. Impact and
 effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of
 vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi,
 2006–18: prospective observational time-series and case-control studies. Lancet Glob
 Health. Elsevier; 2021;9: e989–e998. doi:10.1016/S2214-109X(21)00165-0
- 535 10. Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, et al. Serotype
 536 Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period:

537 538		Findings from the PSERENADE Project. Microorganisms. Multidisciplinary Digital Publishing Institute; 2021;9: 738. doi:10.3390/microorganisms9040738
539 540 541 542	11.	Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nat Commun. Nature Publishing Group; 2020;11: 2222. doi:10.1038/s41467-020-15786-9
543 544 545	12.	Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa. Expert Rev Vaccines. Taylor & Francis; 2020;0: 1–8. doi:10.1080/14760584.2020.1843435
546 547	13.	VACFA. Immunization Schedules - Africa Vaccines for Africa [Internet]. 13 Apr 2018 [cited 27 Aug 2020]. Available: http://www.vacfa.uct.ac.za/immunization-schedules-africa
548 549 550 551	14.	Matanock A. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68. doi:10.15585/mmwr.mm6846a5
552 553 554 555	15.	Chen C, Wood JG, Beutels P, Menzies R, MacIntyre CR, Dirmesropian S, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018;36: 1265–1271. doi:10.1016/j.vaccine.2018.01.052
556 557 558 559	16.	Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CMS, Brandileone MC de C, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Hum Vaccines Immunother. Taylor & Francis; 2016;12: 285–292. doi:10.1080/21645515.2015.1117713
560 561 562 563	17.	Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine. 2019;6: 42–50. doi:10.1016/j.eclinm.2018.12.007
564 565 566 567	18.	Cohen C, Mollendorf C von, Gouveia L de, Lengana S, Meiring S, Quan V, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017;5: e359–e369. doi:10.1016/S2214-109X(17)30043-8
568 569 570	19.	Choi YH, Andrews N, Miller E. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study. PLOS Med. 2019;16: e1002845. doi:10.1371/journal.pmed.1002845
571 572 573 574	20.	Brandileone M-CC, Almeida SCG, Minamisava R, Andrade A-L. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36: 2559–2566. doi:10.1016/j.vaccine.2018.04.010

575 576 577 578	21.	Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30: 6802–6808. doi:10.1016/j.vaccine.2012.09.019
579 580 581 582	22.	Neto JT, Tannus Branco de Araujo G, Gagliardi A, Pinho A, Durand L, Fonseca M. Cost- effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. Hum Vaccin. Taylor & Francis; 2011;7: 1037–1047. doi:10.4161/hv.7.10.15987
583 584 585	23.	Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9: 1469–1502. doi:10.21037/jtd.2017.05.31
586 587 588 589 590 591 592	24.	WasmÆlia B, Nuno Duarte da Costa B, Marcia Maria Melo Q, Wadih Jo ^a o Scandar N, Paulo CØsar Morae S, David Wu T, et al. Censo Demografico 2010 Brazil. Características da população e dos domicílios Resultados do universo [Internet]. Rio de Janeiro, RJ - Brasil: Instituto Brasileiro de Geografi a e Estatística; 2011 pp. 1–270. Report No.: 3. Available: https://biblioteca.ibge.gov.br/visualizacao/periodicos/93/cd_2010_caracteristicas_populaca o_domicilios.pdf
593 594 595 596 597	25.	Office for National Statistics UK. Estimates of the Population for the UK, England and Wales, Scotland and Northen Ireland 2017 [Internet]. Office for National Statistics; 2017 Jun. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populatio nestimates
598 599 600 601 602 603 604	26.	National Statistical Office Malawi. Malawi Population and Housing Census 2018 [Internet]. Zomba, Malawi, and Rockville, Maryland, USA: National Statistical Office Malawi; 2019 May pp. 1–311. Report No.: 4. Available: http://www.nsomalawi.mw/index.php%3Foption%3Dcom_content%26view%3Darticle%2 6id%3D226:2018-malawi-population-and-housing- census%26catid%E2%80%89%3D%E2%80%898:reports%26Itemid%E2%80%89%3D%E 2%80%896
605 606	27.	Statistics South Africa. South Africa Population Census 2011 [Internet]. Statistics South Africa; 2011. Available: http://www.statssa.gov.za/?page_id=3992
607 608	28.	World Bank Group. World Population Annual Growth [Internet]. 10 Aug 2021 [cited 10 Aug 2021]. Available: https://data.worldbank.org/indicator/SP.POP.GROW?
609 610	29.	Johnson L, Dorrington R. Thembisa Project - A Mathematical Model of South African HIV epidemic [Internet]. 8 Feb 2022 [cited 8 Feb 2022]. Available: https://www.thembisa.org/
611 612	30.	Fox GA, Kendall BE. Demographic Stochasticity and the Variance Reduction Effect. Ecology. 2002;83: 1928–1934. doi:10.1890/0012-9658(2002)083[1928:DSATVR]2.0.CO;2

613 614 615	31.	Chaguza C, Heinsbroek E, Gladstone RA, Tafatatha T, Alaerts M, Peno C, et al. Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data. Clin Infect Dis. 2020;70: 1294–1303. doi:10.1093/cid/ciz404
616 617 618	32.	Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570: 189. doi:10.1038/s41586-019-1200-9
619 620 621 622	33.	Wright LB, Hughes GJ, Chapman KE, Gorton R, Wilson D. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006–July 2012. Trials Vaccinol. 2013;2: 45–48. doi:10.1016/j.trivac.2013.09.004
623 624 625	34.	Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine. 2013;31: 5863–5871. doi:10.1016/j.vaccine.2013.09.049
626 627 628 629 630	35.	Rodríguez MAG, Gavín MAO, García-Comas L, Moreno JCS, Deorador EC, Carbajo MDL, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Eurosurveillance. European Centre for Disease Prevention and Control; 2014;19: 20922. doi:10.2807/1560-7917.ES2014.19.40.20922
631 632 633	36.	Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372: 1114–1125. doi:10.1056/NEJMoa1408544
634 635 636 637	37.	Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 2016;5: 92–96. doi:10.1016/j.trivac.2016.04.004
638 639 640	38.	van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJM. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. Clin Infect Dis. 2015;61: 1835–1838. doi:10.1093/cid/civ686
641 642 643	39.	Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, et al. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021;40: 944–951. doi:10.1097/INF.000000000003277
644 645 646 647 648 649 650	40.	Merck. Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company's Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults. In: Merck.com [Internet]. [cited 10 Jul 2022]. Available: https://www.merck.com/news/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ/

- 41. Weinberger DM, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for
 Adults. JAMA Intern Med. 2017;177: 303–304. doi:10.1001/jamainternmed.2016.8289
- 42. Flasche S, Lipsitch M, Ojal J, Pinsent A. Estimating the contribution of different age strata
 to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study.
 BMC Med. 2020;18: 129. doi:10.1186/s12916-020-01601-1
- Kobayashi M. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent
 Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the
 Advisory Committee on Immunization Practices United States, 2022. MMWR Morb
 Mortal Wkly Rep. 2022;71. doi:10.15585/mmwr.mm7104a1
- 44. Linley E, Bell A, Gritzfeld JF, Borrow R. Should Pneumococcal Serotype 3 Be Included in
 Serotype-Specific Immunoassays? Vaccines. Multidisciplinary Digital Publishing Institute;
 2019;7: 4. doi:10.3390/vaccines7010004